REFLODX, INC.

Medtech · Private

Noninvasive ultrasound device with proprietary algorithms that detects gastroesophageal reflux via acoustic signatures from esophageal wall changes

Grants
$1.5M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Novel Device for detecting changes in the esophageal lumen using single point ultrasonic transducers$225,000
Federal grantNational Science Foundation · Phase I · STTR Phase I: SondeFlux, a novel, low-cost, noninvasive device to detect and characterize the presence or absence of a bolus in the upper esophagus.$249,999
Federal grantNational Science Foundation · Phase II · SBIR Phase II: A novel, low-cost, noninvasive device to detect and characterize the presence or absence of a bolus in the upper esophagus.$1,000,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1872Narnar, LLC——
1873E-Msion, Inc.——
1874Quantum NanoStim LLC——
1875REFLODX, INC.——
1876Smart Skin Technologies Inc.—$85K
1877CLEARVOYA LLC——
1878SILICON AUDIO, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.